Acrivon Therapeutics, Inc.
ACRVNasdaqCIK 1781174HealthcareFiscal year ends Dec 31
Reports and events: 71 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1216:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-346859 |
| 2026-08-1216:05 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-346819 |
| 2026-06-1717:28 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-274410 |
| 2026-05-1316:12 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-221634 |
| 2026-05-1316:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-221626 |
| 2026-04-3008:30 ET | DEF 14A | Proxy statementPeriod 2026-06-17 | 0001193125-26-194206 |
| 2026-04-2316:29 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000116 |
| 2026-03-2316:28 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000081 |
| 2026-03-1907:21 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-115139 |
| 2026-03-1907:10 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-115123 |
| 2026-03-0216:30 ET | 8-K | 1.02 Termination of a material agreement | 0001193125-26-085516 |
| 2026-02-2709:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-079500 |
| 2026-01-0809:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-007077 |
| 2026-01-0807:30 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-007007 |
| 2025-11-1316:17 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-280215 |
| 2025-11-1316:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-280172 |
| 2025-09-0516:25 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-197250 |
| 2025-08-1316:16 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-108054 |
| 2025-08-1316:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-179834 |
| 2025-06-1316:28 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-086246 |
| 2025-05-1416:16 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-071427 |
| 2025-05-1416:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-071385 |
| 2025-04-2508:30 ET | DEF 14A | Proxy statementPeriod 2025-06-13 | 0000950170-25-058352 |
| 2025-04-0716:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-051576 |
| 2025-03-2716:48 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-046163 |
| 2025-03-2716:06 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-046056 |
| 2025-03-2517:15 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-044549 |
| 2025-03-1416:44 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-039520 |
| 2024-11-1307:06 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125929 |
| 2024-11-1307:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125920 |
| 2024-10-1108:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-114213 |
| 2024-09-1606:43 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-219180 |
| 2024-08-1308:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095766 |
| 2024-08-1307:36 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-095760 |
| 2024-06-2117:36 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-075760 |
| 2024-05-1408:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-059097 |
| 2024-05-1407:31 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-059084 |
| 2024-04-2608:30 ET | DEF 14A | Proxy statementPeriod 2024-06-20 | 0000950170-24-048671 |
| 2024-04-2416:01 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-047560 |
| 2024-04-1116:16 ET | SC 13D/A | Ownership report, active investor, amended | 0001104659-24-046306 |
| 2024-04-0907:05 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-042789 |
| 2024-03-2808:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-037627 |
| 2024-03-2807:36 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-037618 |
| 2024-03-0408:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-056937 |
| 2024-02-0808:27 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-027629 |
| 2024-01-0807:28 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-003885 |
| 2023-12-0816:21 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-291705 |
| 2023-11-0909:12 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-274124 |
| 2023-11-0908:02 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-061553 |
| 2023-09-0517:23 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-228639 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 16:05 ET. Listed shows no prices and gives no investment advice.